Background: This study was performed to compare the effects of low dose interferon beta-1 (IFN-β-1) (CinnoVex, 30 mcg) and high dose IFN-β-1 (REBIF, 44 mcg) on the reduction of the number and size of plaques in magnetic resonance imaging (MRI) in patients with multiple sclerosis (MS). Methods: This historical cohort study, which was performed in 2014 in Sanandaj (western part of Iran). 43 MS pa...

1. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336:1224-34. 2. Pietropaoli A, Modrak J, Utell M. Interferon-α therapy associated with the development of sarcoidosis. Chest 1999; 116:569-72. 3. Kikawada M, Ichinose Y, Kunisawa A, et al. Sarcoidosis induced by interferon therapy for chronic myelogenous leukaemia. Respirology 1998; 3:41-4. 4. Hoffman RM, Jung MC, Motz R, et al. S...

Objectives Protosappanin A (PrA) is an effective and major ingredient of Caesalpinia sappan L. The current study was aimed to explore the effect of PrA on atherosclerosis (AS). Materials and Methods Firstly, the experimental model of AS was established in rabbits by two-month feeding of high fat diet. Then, the rabbits were randomly divided into five groups and treated with continuous high li...

background cutaneous leishmaniasis is a health problem in the world. lesions should be treated on cosmetically or functionally important sites, such as the face and hands. cantharidin is a terpenoid compound produced naturally by beetles of meloidae and oedemeridae families. objectives the current study aimed to investigate the effect of cantharidin on cutaneous leishmaniasis (cl) lesions and i...

Mammalian cells utilize a wide spectrum of pathways to antagonize the viral replication. These are typically regulated by antiviral proteins and can be constitutively expressed but also exacerbated interferon induction. A myriad interferon-stimulated genes (ISGs) have been identified in mounting broad-spectrum responses. Members interferon-induced transmembrane (IFITM) family unique among these...

Background. Current treatment of chronic hepatitis C with pegylated interferon and ribavirin has the ability to eliminate viral infection in about half of the patients treated. Therapeutic options, for those with remaining chronic hepatitis, will remain limited until novel antivirals become available in the future. Consensus interferon is currently available and has demonstrated clinical effica...